Novo Nordisk says it will seek regulatory approval soon to sell its Wegovy weight-loss pill in China, according to statements by the company’s chief executive. The move is aimed at expanding access to the treatment in the world’s second-largest pharmaceutical market. The company’s plans also reflect competitive pressure in China’s obesity and weight-management segment, where rival Eli Lilly has already advanced with its own weight-loss offerings.
Both reports indicate the focus is on obtaining the necessary authorization for an oral formulation of Wegovy rather than continuing to rely on existing delivery methods. Details about timing, regulatory pathway, or potential launch date after approval are not specified in the provided excerpts. The information presented centers on the company’s intention to begin the approval process in the near term in China, positioning Wegovy to better compete with alternative therapies available or under development in the market.
